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Abstract
Hepatocarcinogenesis is a multistep process, heralded by
abnormalities in cell differentiation and proliferation and
sustained by an aberrant neoangiogenesis. Understanding
the underlying molecular pathogenesis leading to hepato-
cellular carcinoma is a prerequisite to develop new drugs
that will hamper or block the steps of these pathways. As
hepatocellular carcinoma has higher arterial vascularization
than normal liver, this could be a good target for novel
molecular therapies. Introduction of the antiangiogenic drug
sorafenib into clinical practice since 2008 has led to new
perspectives in the management of this tumor. The impor-
tance of this drug lies not only in the modest gain of patients’
survival, but in having opened a roadmap towards the
development of new molecules and targets. Unfortunately,
after the introduction of sorafenib, during the last years, a
wide number of clinical trials on antiangiogenic therapies
failed in achieving significant results. However, many of these
trials are still ongoing and promise to improve overall survival
and progression-free survival. A recent clinical trial has
proven regorafenib effective in patients showing tumor pro-
gression under sorafenib, thus opening new interesting
therapeutic perspectives. Many other expectations have been
borne from the discovery of the immune checkpoint blockade,
already known in other solid malignancies. Furthermore, a
potential role in hepatocellular carcinoma therapy may derive
from the use of branched-chain amino acids and of nutritional
support. This review analyses the biomolecular pathways of
hepatocellular carcinoma and the ongoing studies, the actual
evidence and the future perspectives concerning drug ther-
apy in this open field.
Citation of this article: Rinninella E, Cerrito L, Spinelli I,
Cintoni M, Mele MC, Pompili M, et al. Chemotherapy for
hepatocellular carcinoma: current evidence and future
perspectives. J Clin Transl Hepatol 2017;5(3):235–248. doi:
10.14218/JCTH.2017.00002.
Introduction
Epidemiology
Hepatocellular carcinoma (HCC) is the sixth most frequent
neoplasia (749,000 new cases/year), with a constantly increas-
ing worldwide incidence and about 745,000 deaths/year.1 It
represents the third cause of tumor-related death (692,000
cases/year), and its incidence is higher in males (M/F ratio of
2.4), mainly affecting people in the sixth to seventh decade of
life.2,3 The incidence of HCC is higher in Chinese and black-
African populations, representing 85% of all HCC diagnoses
worldwide; moreover, younger patients are usually involved,
especially for the hepatitis B virus (HBV)-related cirrhosis.
Hepatitis C virus (HCV)-related liver disease, on the other
hand, is the main cause of chronic liver disease leading to
HCC in Europe, the United States and Japan.2 In general, in
developed countries (Europe, the United States and Japan)
the incidence is low, with the exception of Southern Europe.4
Risk factors
In 90% of cases, HCC is associated with a well-identified risk
factor, the most important of which are HBV and HCV chronic
hepatitis, alcohol intake and exposure to toxic agents (e.g.
aflatoxin B). HBV infection is predominant in Eastern Asia and
Africa (60%), while HCV is predominant in Europe, Japan and
Northern America (50–60%). According to global incidence,
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54% cases of HCC are due to HBV infection and 31% to
HCV.5,6
HBV is a risk factor for HCC in both cirrhotic livers (annual
incidence of 2–6%) and non-cirrhotic ones (annual incidence
of 0.5%).7 In the latter case, HBV directly acts as a carcino-
genic factor through its integration in the hepatocyte genome,
determining genomic instability.8,9 Exposure to aflatoxin
enhances the possibility of generating HCC, especially in the
case of concurrent HBV infection;10 this is frequent in devel-
oping nations, where food conservation is altered by poor life-
style and climatic conditions.11
In the majority of cases, HCC emerges in cirrhotic livers,
with an estimated risk of 3–4% patients per year, regardless
of etiology;12 chronic viral infection (HBV, HCV) and alcoholic
liver disease are the most well known risk factors. Auto-
immune hepatitis, primary biliary cholangitis, inheritedmetabolic
diseases (hemochromatosis, alpha-1-antitrypsin deficiency,
and Wilson’s disease) are other less frequent risk factors.13–15
Obesity, non-alcoholic fatty liver disease and diabetes mellitus
have been recently associated with advanced liver fibrosis.16
Current evidence indicates that these factors, and in particular
insulin-resistance, are also clearly associated with HCC.17–19
On the other hand, observational studies have shown that the
use of metformin and statins could prevent the risk of HCC,20
but randomized clinical trials are unavailable on this topic.
Standard-of-care
The therapeutic strategy for HCC is defined by the Barcelona
Clinic Liver Cancer (BCLC) classification, which considers the
three important variables of tumor staging (size, number of
nodules, vascular invasion and/or extrahepatic disease), liver
function evaluation (using the Child-Pugh score) and per-
formance status (PS), according to the Eastern Cooperative
Oncology Group (ECOG).21
In the early stages and according to tumor location and
number, liver function and portal hypertension assessment,
surgical resection and percutaneous ablation (including radio-
frequency ablation (RFA), microwave ablation (MWA) and
percutaneous alcohol injection (PEI)) are the main therapeu-
tic strategies. Liver transplantation may be taken into account
in patients younger than 70 years old without significant
comorbidities and with HCC staged within Milan or slightly
enlarged criteria (up to seven, according to the University of
California, San Francisco), independent from the degree of
liver function failure or portal hypertension.22–24
Trans-arterial chemoembolization (TACE) should be offered
to patients with intermediate BCLC tumor stage (preserved
function, PS = 0, large or multifocal tumors, no vascular inva-
sion or extra-hepatic spread).21,25,26 Advanced HCC in compen-
sated patients are treated with sorafenib. To date, it represents
the only systemic therapy with a documented improvement in
overall survival (OS).27 Even if there are not yet results from
prospective randomized clinical trials, Yttrium 90 trans-arterial
radio embolization (TARE) is an effective tool, often used in
large specialized centers for the treatment of intermediate-
advanced HCC with unfavorable predictors of response or
non-responders to TACE, such as patients with macroscopic
vascular invasion.28,29 In some circumstances, it has been
used as a bridge to liver transplantation.30
Curative strategies (resection, PEI, RFA, liver transplanta-
tion) are limited to the early stage, cases of which account
for less than 40% of the neo-diagnoses of HCC. Palliative
treatments (TACE, sorafenib and TARE) are effective but they
can only prolong survival.21
Advanced HCC: the field of molecular
target therapies
Molecule-targeted therapies represent a new promising field
in advanced HCC treatment. They are based on the identi-
fication of different carcinogenetic mechanisms.
Classical molecular targets in HCC
Molecular mechanisms involved in the pathogenesis of HCC
are represented by altered intracellular signal transmission as
well as angiogenetic and growth factors. Accordingly, specific
targets were established for the treatment of HCC. Currently
established treatments are represented by tyrosine kinase
inhibitors and monoclonal antibodies.
The most evaluated molecular intracellular pathways, to
date, are the following (Fig. 1):
 Ras/Raf/MEK/ERK (MAPK) pathway, characterized
by the phosphorylation of four major kinases: Ras, Raf,
mitogen-activated protein extracellular kinase (MEK), and
extracellular signal-regulated kinase (ERK). This pathway is
the most frequently hyper-activated in HCC (about 50% of
early stage cases and the majority of advanced ones).31
 Wnt/catenin pathway, characterized by the Wnt protein
binding to its ligand, which results in the accumulation and
activation of b-catenin in cells that in turn is rapidly trans-
ferred to the nucleus, where it regulates transcriptional
mechanisms. Around 50% of all patients with HCCs have
activation of the WNT signaling pathway.32,33
 Phosphoinositol 3-kinase (PI3K)/Akt/mammalian
target of rapamycin (mTOR) pathway, activated in
30–50% of HCCs.34 It is localized downstream of several
receptor tyrosine kinases (e.g. ERK), controlling cellular
replication, apoptosis and cell motility, and involved in inva-
siveness and metastasis.35,36 PI3K is partially controlled by
the tumor suppressor phosphatase and tensin homolog
(PTEN) protein, that is frequently mutated in HCC.37 The
overstimulation of this pathway leads to the inactivation
of some apoptotic mechanisms, determining the hyper-
activation of mTOR, an enzyme serving a pivotal role in
cellular proliferation and angiogenesis.38
Several growth factors (and their receptors) involved in
hepatic carcinogenesis have been identified. HCC is a highly
vascularized tumor and both vascular endothelial growth
factor (VEGF) and angiopoietin-2 (Ang-2) are key elements
for tumor emergence and proliferation; in particular, VEGF
promotes the growth, migration and morphogenesis of endo-
thelial cells, and increases vascular permeability.39,40 A vas-
cular targeting approach is crucial in HCC treatment; several
studies have demonstrated that high-density vascularization
is a predictor of poor response to treatment and shorter
disease-free period after hepatic resection.41,42 Platelet
derived growth factor (PDGF) determines the involvement
of pericytes and smooth muscle cells around the new vascular
shoots.43 These factors are strictly related to metastatic
potential of tumor cells; for this reason, their inhibitors are
a promising therapeutic agent.44
Epidermal growth factor (EGF) is frequently overexpressed
in HCC;45,46 other involved factors are fibroblast growth
factor (FGF), whose signal are involved in Ras/Raf/MAPK
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pathway and tyrosine protein kinase Met (c-MET), the tyro-
sine kinase receptor for hepatocyte growth factor (HGF).47
The HGF-cMET axis has been implicated in tumor cell migra-
tion, invasion, proliferation, and angiogenesis. High c-Met
and HGF expression correlates with early recurrence of HCC
after hepatectomy and shorter survival in HCC.48
All these agents can become a target for HCC treatment,
alone or combined with each other or to other strategies
(loco-regional treatment or resection), as previous and recent
trials have demonstrated.
Role of sorafenib
Traditional chemotherapy agents and hormonal therapies
have been tested for HCC, but they did not improve the
prognosis of these patients. An important frontier was
reached with the introduction of sorafenib, a multikinase
inhibitor, in the treatment of advanced HCC. This drug
opened the era of molecular targeted therapy for HCC and
represents the current first-line pharmacological treatment
for advanced HCC.
Sorafenib is a tyrosine kinase inhibitor, targeting Raf
serine/threonine kinases, vascular endothelial growth factor
receptors 1–3 (VEGFR1–3), platelet-derived growth factor
receptor (PDGFR)-b, tyrosine-protein kinase Kit (c-Kit), fms-
like tyrosine inase-3 (FLT-3) and p38 tyrosine kinases.49 Its
use in advanced HCC was approved in 2008, on the basis of
the positive results of two multicenter, phase 3 studies (the
so-called SHARP and Asia-Pacific trials).27,50
SHARP was a phase 3 randomized placebo-controlled
study involving 602 patients with advanced HCC (299 receiv-
ing sorafenib and 303 receiving placebo). An improvement
in OS was demonstrated in the sorafenib arm: 10.7 versus
7.9 months (hazard ratio [HR] in the sorafenib group, 0.69;
95% confidence interval [CI]: 0.55 to 0.87; p < 0.001).27
A similar result was obtained by the Asia-Pacific trial (6.5
versus 4.2 months for sorafenib and placebo respectively, HR
0.68 [95% CI: 0.50−0.93]; p = 0.014). Sorafenib-related
Fig. 1. Main molecular pathways in HCC pathogenesis. (A) The activation of Frizzled (WNT receptor) determines the recruitment of disheveled (DSH), preventing the
destruction of b-catenin through the dissolution of a molecular complex composed by Axin, adenomatosis polyposis coli (APC), and glycogen synthase kinase 3b (GDK3B).
(B) Growth factors bind their specific receptors, leading to their dimerization and activation of the tyrosine-kinase. From this point, it is possible to recruit two different groups
of molecules: MAPK and PI3K pathways, culminating with modifications in cell-cycle regulation, protein synthesis, and gene transcription. (C) Stimulation of TGF-bR recruits
the SMAD complex, leading to a negative regulation of the cellular cycle. (D) CTLA-4 and its ligands: CD-80/CD-86 transmit an inhibitory signal in the antigen presenting cells
(APCs), while CD-28 represents an activating signal. Programmed cell death protein-1 (PD-1), through its binding to PD-L1 (B7-1) and PD-L2 (B7-2), down-regulates the
immune system and promotes self-tolerance. Adapted from Harding et al.121
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major adverse effects are diarrhea, hand-foot skin reaction
(HFSR), fatigue and weight loss. In the SHARP trial, the
overall incidence of treatment-related adverse events (AEs)
was 80%, of which most were described as grade 1 or 2 in
severity. Some grade 3 AEs, such as diarrhea (8% vs 2% in
the placebo group, p < 0.001) and HSFR (8% vs <1%, p <
0.001), occurred more frequently in the sorafenib group. The
trial was prematurely stopped at second interim analysis for a
significant survival benefit in the sorafenib arm.
For better understanding of efficacy and safety in real
practice, a prospective multicenter observational study was
conducted in six Italian referral hospitals.51 That study
enrolled 296 patients affected by HCC in BCLC C stage
(222, 75%) or BCLC B stage (74, 25%), who were unfit for
or failed to respond to loco-regional treatments. Median OS
was 10.5 months in the overall cohort, with results showing
8.4 months in the BCLC C patients versus 20.6 months in
the BCLC B patients (p < 0.0001). The overall incidence of
treatment-related AEs was higher than in the SHARP study
(91%), with a greater percentage of grade 3 and 4 AEs,
such as fatigue (25%) and arterial hypertension (7%). Discon-
tinuation, dose reduction and interruption were greater than in
the SHARP study. Surprisingly, a dose reduction for AEs was
associated with a better OS: 21.6 months in the patients
receiving a half-dose of sorafenib (95% CI: 13.6–29.6) com-
pared to 9.6 months (95% CI: 6.9–12.3) for the remaining
patients, who remained at full dose.
The multivariate analysis confirmed that “full dose” treat-
ment was an independent predictor of mortality (HR: 1.8,
95% CI: 1.4–2.4). Dose reduction for AEs is common in real-
life practice and may improve the treatment tolerability,
following adjusting of the drug dosage to the patient;52
however, in a propensity score matching study, no differences
in terms of OS and progression-free survival (PFS) have been
reported between initial “half-dose” and “standard-dose”
treatments.53 Indeed, a better outcome may be more related
to an increased incidence of AEs leading to dose reduction,
than to the dose itself. This result is better understood in the
light of other observational studies showing that early AEs
(such as diarrhea or HFSR) are positive predictive factors
for clinical response to sorafenib therapy.54,55
Given the hypothesis that loco-regional treatments may
increase the production of angiogenic factors, particularly
VEGF and thus enhancing angiogenesis and metastasis,56
sorafenib was then evaluated as adjuvant therapy in combi-
nation with curative (resection, ablation) or loco-regional pal-
liative treatments (such as TACE). The STORM trial phase 3
study explored the efficacy of sorafenib as adjuvant treat-
ment for preventing HCC recurrence after surgical resection
or ablation, but it failed to demonstrate a better efficacy in
terms of recurrence-free survival.57 On the other hand, the
phase 3 Sorafenib or Placebo in Combination with Transarte-
rial Chemoembolization (known as the SPACE trial), failed to
demonstrate a longer time to progression (TTP) in the sora-
fenib arm (compared to placebo) after doxorubicin-eluting
beads TACE.58
To date, new treatments are clearly needed as alternatives
to sorafenib or for administration after sorafenib failure.
Other first-line promises
Despite a vast number of trials studying new possible
therapies for advanced HCC, almost all phase 3 trials failed
to show better outcomes than sorafenib in the first-line
setting (Table 1);59–62 consequently, no other systemic treat-
ments are approved for advanced HCC. Only two drugs are
still being tested in phase 3 trials compared in first-line to
sorafenib in advanced HCC. The first one is lenvatinib, an
antiangiogenic small molecule, and the second one is nivolu-
mab, an immune check-point inhibitor (see below).
Lenvatinib
Lenvatinib is an oral multikinase inhibitor targeting VEGF1–3,
fibroblast growth factor receptors 1–4 (FGFR1–4), RET, c-kit,
stem cell growth factor receptor (SCGFR) and PDGFRa. It has
antiangiogenic and direct antitumor activity.63 According to
results of two large randomized trails (phase 3 and 2)64,65 it
has been recently approved by the Food and Drug Adminis-
tration (FDA) for the treatment of adult patients with radio-
active iodine refractory thyroid carcinoma and for adult
patients with advanced renal cell carcinoma who have been
previously treated with VEGF inhibitor. In the latter case, it is
combined with everolimus. Themost common side effects are
those of other antiangiogenic drugs: hypertension, fatigue,
proteinuria, nausea, decreased weight, abdominal pain, and
HFSR.
For advanced HCC, a phase 2, single-arm, open-label
multicenter study was conducted.66 Forty-six patients were
enrolled at sites across Japan and Korea; the primary end-
point, median TTP, was 7.4 months (95% CI: 5.5–9.4). Sev-
enteen patients (37%) reported partial response (PR) and
19 patients (41%) had stable disease (SD) according to
Response Evaluation Criteria in Solid Tumors (RECIST)
version 1.1.67 The median OS was 18.7 months (95% CI:
12.7–25.1). Moving forward based on these positive results,
a multicenter, randomized, open-label, sorafenib controlled,
non-inferiority phase 3 trial was planned and performed in
patients affected with unresectable HCC.68 That trial is
ongoing but no longer recruiting, and therefore it is possible
that results will be available in the near future.
Second-line therapies
Among second-line attempts to overcome sorafenib failure,
many drugs have themselves failed (Table 2). In particular,
brivanib, a selective dual inhibitor of VEGFR and FGFR tyro-
sine kinases, did not show in the phase 3 BRISK-PS study69
a significant gain in survival compared to placebo (9.4 vs
8.2 months, HR: 0.89; 95.8% CI: 0.69 to 1.15; p = 0.3307),
despite a longer TTP (4.2 vs 2.7 months; HR: 0.56; 95%
CI: 0.42 to 0.76; p < 0.001) and a greater overall response
rate (ORR) (10% vs 2%, Odds ratio: 5.72) according to
mRECIST criteria.70 In the same way, everolimus, an mTOR
inhibitor, and erlotinib, an EGFR inhibitor, did not demonstrate
the ability to prolong OS compared to placebo in patients pro-
gressing during sorafenib treatment or who were intolerant to
the drug.62,71
A peculiar interest is still present for ramucirumab. It is an
intravenous recombinant immunoglobulin (Ig)G1 monoclonal
antibody directed against VEGFR-2.72 Efficacy and safety in
the HCC setting have been largely tested in a phase 3, rando-
mized, placebo-controlled, double-blind, multicenter trial
(known as REACH).73 Eligible patients were adult patients
with advanced HCC who had previously stopped sorafenib
due to progression or intolerance. Five-hundred-and-sixty-
five patients were enrolled, of whom 283 were assigned to
the ramucirumab group and 282 were assigned to the
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placebo group. The median OS gain in the ramucirumab
group did not reach statistical significance versus the placebo
arm (9.2 vs 7.6 months, HR: 0.87, 95% CI: 0.72–1.05;
p = 0.14). The safety profile was manageable; the most fre-
quent treatment-emergent serious AE (grade 3 or more) was
malignant neoplasm progression (6% in the ramucirumab
group vs 4% in the placebo group). In a subgroup analysis
of patients with Child A functional status and baseline
a-fetoprotein (aFP) levels of 400 ng/mL or more, patients
who received ramucirumab did achieve significantly longer
OS compared with those who received placebo (for Child A5
patients, HR was 0.61, 95% CI: 0.43–0.87; p = 0.01).74 This
result provided the clinical basis for planning another phase 3
trial (titled as REACH-2), recruiting patients who progressed
or are intolerant to sorafenib with a baseline aFP of 400 ng/mL
or more. The trial is now ongoing and recruiting patients.75
The estimated study completion date is April 2018.
Recently, positive results from a large phase 3 study on
regorafenib have been published.76 Regorafenib is an oral
multikinase inhibitor, pharmacologically similar but more
potent than sorafenib, that blocks kinases involved in angio-
genesis (VEGFR1–3 and TIE2), oncogenesis (c-kit, Ret and
wild-type and V600-mutated BRAF) and the tumor microen-
vironment (PDGFR and FGFR).77 It is actually approved
as monotherapy for the treatment of refractory metastatic
colorectal cancer and gastrointestinal stromal tumor.78 In
the RESORCE study,76 a randomized, double-blind, placebo-
controlled, phase 3 trial, 567 patients affected by HCC were
randomized to receive regorafenib (n = 374) or placebo
(n = 193) after sorafenib failure for progression (patients
stopping sorafenib for AEs were not included). Regorafenib
was demonstrated to be effective in improving OS as
second-line therapy (10.6 vs 7.8 months in the placebo
arm; HR 0.63, 95% CI: 0.50–0.79; p < 0.0001). Regorafenib
also reached the secondary endpoints of PFS (HR 0.46, 95%
CI: 0.37–0.56; p < 0.0001) and TTP (HR: 0.44, 95% CI:
0.36–0.55; p < 0.0001). The safety profile appears similar
to that of the other antiangiogenic drugs, with the most
common grade 3 or 4 AEs being hypertension (15% in the
regorafenib group vs 5% in the placebo group), HFSR (13%
vs 1%), fatigue (9% vs 5%) and diarrhea (3% vs 0%). Regor-
afenib is hence a new tool in the systemic therapy for HCC
after failure of sorafenib therapy. Nevertheless, it has not
been tested in patients stopping sorafenib for AEs, in whom
it could be scarcely tolerated.
Another new promising tool in second-line chemotherapy
after sorafenib is tivantinib. Tivantinib is an oral selective
inhibitor of c-MET.79 Positive results have been obtained from
a randomized phase 2 trial, comparing tivantinib versus
placebo in second-line treatment (after sorafenib failure or
intolerance) in patients affected by HCC.80 The trial enrolled
107 patients, including 71 patients who received tivantinib
(38 at 360 mg twice-daily and 33 at 240 mg twice-daily)
and 36 patients who received placebo. A slightly significant
improvement in TTP was obtained in the tivantinib arm for
the overall population; however, better outcomes were
reached in terms of OS (7.2 vs 3.8 months of the placebo
arm; HR: 0.38, 95% CI: 0.18–0.81; p = 0.01) and TTP (2.7
vs 1.4 months respectively; HR: 0.43, 95% CI: 0.19–0.97;
p = 0.03) in a subset of patients whose tumor tissues had
an overexpression of MET at immunohistochemistry (MET-
high patients). The most common grade 3 or worse AEs in
the tivantinib group were neutropenia (14% vs none in the
placebo group) and anemia (11% vs 0% in the placebo
T
a
b
le
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group). Four deaths due to tivantinib-related neutropenia were
reported. Grade 3 or more neutropenia was more common in
the 360 mg twice-daily dose group than in 240 mg twice-daily
group (21% vs 6% respectively). Given the survival benefit in
the MET-high population, two large randomized, double-blind,
placebo-controlled phase 3 studies have been designed to
enroll MET-high inoperable HCC patients in Europe, America,
Australia (known as the METIV-HCC)81 and Asia (known as the
JET-HCC).82 The first trial is ongoing and not recruiting partic-
ipants any longer, but the latter is still recruiting. The daily
dosage in the tivantinib arm is 120 mg twice-daily (total daily
dose of 240 mg). The results will soon be available.
Another MET inhibitor is cabozantinib. Its action comprises
the inhibition of numerous tyrosine kinase receptors as well,
such as VEGFR2, KIT, RET, FLT3 and Tie-2.83 Cabozantinib
was tested in the HCC setting, after a first antiangiogenic
therapy failure, in a phase 2 study.84 The treatment showed
effectiveness in reaching a PFS of 4.2 months with an overall
disease control rate (DCR) at week 12 of 68%. To date, a
phase 3, placebo-controlled trial is ongoing in patients
with HCC progressing during sorafenib therapy or showing
intolerance to the drug.85 The study is estimated to enroll
760 patients and it could offer results in the next months.
Immune checkpoint inhibitors in HCC: a look
into the future
Moving forward, a great interest has spread in anticancer
therapy on the so-called “immune check-point inhibitors”. The
liver is a “tolerogenic” organ, expecting to receive a large
amount of antigens absorbed from the gut. This tolerance is
mediated by immunosuppressive cell populations, such as
T regulatory cells (Tregs), myeloid-derived suppressor cells
and antigen presenting cells (APCs). Among these, there are
Kuppfer cells, macrophages and modulatory dendritic cells.86
Notably, the high number of these immunomodulatory cells in
HCC tissue is correlated with disease progression and worse
prognosis in HCC patients.87 Some inhibitory molecules,
called “immune checkpoints”, have been recognized in the
physiologic maintenance of tolerance. The most cited are
“programmed cell Death protein 1” (PD-1) and “cytotoxic T
lymphocyte antigen-4” (CTLA-4).
PD-1 is a cell surface receptor of the Ig superfamily,
expressed on T cells, B cells, and natural killer cells. PD-1
binds two ligands, PD-L1 and PD-L2, expressed on APCs. The
binding of PD-L1 to PD-1 transmits an inhibitory signal which
reduces the proliferation of CD8+ T cells88 and cytokine
release.89 PD-1 also mediates immunotolerance through the
differentiation and proliferation of Tregs.90 Clinical studies
have shown that chronic viral infections may up-regulate
the PD-1/PD-L1 pathway, leading to CD8+ T cell exhaustion
and anergy.91 This suggests a role of sustained inflammation
in the genesis of cancer, including HCC. In fact, a CD8+ T cell
response exhaustion is a common finding in HCC and in both
chronic HBV and HCV infection.92
CTLA-4 is a trans-membrane receptor expressed on CD4+
and CD8+ activated cells. After binding with its ligands, CD80
(also called B7–1) or CD86 (B7–2), both expressed on APCs,
it transmits into the lymphocyte an inhibitory signal, contri-
buting to the homeostatic regulation of the immune
response.93 In the HCC setting, the aberrant expression of
these pathways is responsible for the tumor’s evasive mech-
anism from the immune system.94 For this reason, these two
immune check-point molecules are now available for clinical
evaluation.
PD1- PD-L1 Blockade
Nivolumab
Nivolumab is a genetically engineered, fully human monoclo-
nal antibody (IgG4) directed against the negative immunor-
egulatory human cell surface receptor PD-1. Nivolumab binds
to and blocks the activation of PD-1, inhibiting its link to PD-L1
and/or PD-L2. This results in the activation of T cells and cell-
mediated immune responses.95 Its action is employed in
raising immune response against tumor cells or pathogens in
several solid tumors.
Nivolumab is currently approved and in use in patients
with metastatic melanoma, squamous non–small-cell lung
cancer, advanced renal cell carcinoma, Hodgkin lymphoma
and advanced metastatic squamous cell carcinoma of the
head and neck.96 Nivolumab has been tested in a phase 1/2
trial97 in 47 subjects with advanced HCC (n = 24 uninfected;
n = 12 HCV-positive; n = 11 HBV-positive) not amenable to
curative resection. The 68% of subjects had a history of prior
sorafenib exposure. The ORR (partial response+complete
response) was 19% (8/42) with two subjects experiencing
complete responses. The most common (frequency of
$ 15%) treatment-related AEs were increased serum levels
of ALT, AST, lipase, amylase, and skin rash with 4% (2/47) of
subjects withdrawn because of an AE. With the aim of con-
firming and evaluating efficacy and safety, there is now an
ongoing randomized, open-label phase 3 trial, comparing sor-
afenib versus nivolumab as first-line therapy in advanced HCC
(known as CheckMate-459).98 An estimated 726 patients
affected by advanced HCC are randomized 1:1 to receive
nivolumab or sorafenib until disease progression or unaccept-
able toxicity. CheckMate-459 started in November 2015, and
the estimated primary completion date is May 2017. Primary
objectives are OS and TTP. Secondary objectives include ORR,
PFS and evaluation of the relationship between PD-L1 expres-
sion and efficacy.
Durvalumab
Durvalumab (MEDI4736) is a human IgG1 monoclonal anti-
body directed against human PD-L1. The first study in
humans has been a phase 1, multicenter, open-label study,
conducted in adult subjects with advanced solid tumors
refractory to standard therapies or for which no standard
therapies exist.99 In this cohort, a total of 21 HCC patients
were included. Patients received durvalumab every 2 weeks
for a median of 6 doses. The safety profile was acceptable,
with only 2 subjects (10%) experiencing grade 3 or higher
treatment-related AEs. Regarding efficacy, 21% of patients
demonstrated a prolonged SD ($3 months) and there were
no ORs. A phase 2 study to evaluate safety, antitumor activity
and pharmacology of durvalumab in monotherapy or combi-
nation with tremelimumab, an anti CTLA-4 inhibitor (see
above), is currently recruiting participants.100
Pembrolizumab
Pembrolizumab is a highly selective, humanized monoclonal
Ig against PD-1. In a recent case report, it showed a
surprising efficacy in a patient with a HCC extrahepatic
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mass non-responsive to sorafenib therapy, in absence of
significant AEs.101 To date, an open-label, single-center,
single-arm phase 2 trial is ongoing to evaluate efficacy and
safety of pembrolizumab in advanced HCC patients who pro-
gressed or are intolerant to a first-line of antiangiogenic
therapy.102
CTLA-4 Blockade
Ipilimumab
Ipilimumab is a fully humanized anti-CTLA-4 IgG1 antibody,
approved for treating unresectable or metastatic melanoma
in 2011.103 In the HCC setting, ipilimumab is currently being
tested for safety and efficacy (ORR) combined to nivolumab in
patients who are naïve to systemic therapy, using a cohort of
a phase 1/2 trial.104
Tremelimumab
Tremelimumab is a human IgG2 monoclonal antibody specific
for human CTLA-4. Tremelimumab blocks the inhibitory effect
of CTLA-4, and therefore enhances T cell activation. In a
pivotal study, conducted on a small number of patients
affected by HCV cirrhosis-related HCC, it showed an accept-
able safety profile, both anti-viral and anti-tumor activities
(PR: 17.6%, SD: 58.8%).105 A recent study by Duffy et al.100
demonstrated that tremelimumab in combination with tumor
ablation leads to the accumulation of intratumoral CD8+
T cells.106 A phase 2 trial testing tremelimumab combined
with durvalumab or in monotherapy on patients affected by
unresectable HCC with or without HBV or HCV infection, is
ongoing and enrolling patients.
The role of branched-chain amino acids (BCAAs) in HCC
setting
An important reason for the poor prognosis of patients with
HCC is the liver function failure, caused by underlying
cirrhosis.21,25 This condition leads to protein-energy malnu-
trition, due to poor appetite and disorders in protein synthe-
sis, and it is associated with high morbidity and mortality.107
Furthermore, patients with liver cancer often have increased
protein catabolism; a significant proportion of HCC patients
are malnourished or at risk of malnutrition, and this repre-
sents a negative prognostic value in the survival outcome.108
The BCAAs valine, leucine and isoleucine are essential
amino acids with aliphatic branched side chains. Besides
constituting proteins, they are a source of glutamate, which
detoxifies ammonia through glutamine synthesis in skeletal
muscle.109 This property is usually exploited in treating
hepatic encephalopathy, as recommended by international
guidelines.110 The BCAA reduction is an important hallmark
of liver cirrhosis. Several studies demonstrate that BCAA sup-
plementation improves nutritional status, prognosis and
quality of life in these patients.111,112
BCAAs were also found to inhibit hepatocarcinogenesis by
different means, such as the amelioration of insulin resistance
and hyperinsulinemia,113 the improvement of immune func-
tion and the reduction of oxidative stress.114 In addition,
BCAAs may enhance the sensitivity to chemotherapy by
reducing the population of cancer stem cells, which may dif-
ferentiate into cancer cells, through activation of the mTOR
complex 1.115 Moreover, a lot of studies have shown the
usefulness of nutritional supplementation with BCAAs in
patients with HCC undergoing interventions such as surgery,
RFA or TACE.116–118
Takeda et al.119 performed a retrospective cohort study
exploring the effect of BCAA therapy (952 mg of L-isoleucine,
1904 mg of L-leucine and 1144 mg of L-valine given three
times daily after meals) in patients with unresectable HCC
treated with sorafenib. The study showed that OS and the
median administration period of sorafenib in the BCAA group
were significantly longer than those in the control group (p =
0.020 and p = 0.004 respectively). Moreover, after 3 months,
albumin levels in the control group decreased significantly
compared with pretreatment value (p = 0.009), whereas in
the BCAA group there was not a significant decrease from
baseline (p = 0.76); this suggests a role for BCAA in the main-
tenance of albumin levels during sorafenib therapy.
A recent meta-analysis,120 including 11 interventional
studies (surgical or non-surgical procedures) on HCC found
that BCAA-supplemented groups had better outcomes in
terms of survival, albumin levels and lower risk of liver decom-
pensation. In particular, 3-year mortality was statistically lower
in the BCAA groups than in the control groups (37% vs 44%,
p = 0.012), whereas the 1-year survival gain did not reach
statistical significance (18% vs 21%, p = 0.214). The survival
benefit was more evident in Child B patients, confirming a pos-
sible role of BCAA in the maintenance of metabolic homeosta-
sis in moderately decompensated liver cirrhosis.
Thus, oral BCAA supplementation is probably useful for
maintaining hepatic functional reserve in HCC patients. BCAA
use could avoid early discontinuance of therapy and improve
OS in patients with HCC treated with sorafenib, provided that
a correct dosage is administered.
Conclusions
After the revolution brought about by sorafenib introduction
into clinical practice, patients with advanced HCC have been
included in a large number of clinical trials, many of which
have yielded non-significant results. In the first-line setting,
we are waiting for the result of a lenvatinib phase 3 trial.
In second-line field, several antiangiogenic drugs have failed
to demonstrate a gain of efficacy in terms of survival. The
recent positive results achieved with regorafenib have opened
new possibilities in the treatment of patients who progressed
on sorafenib. Considerable efforts are being invested in the so-
called “immune check-point blockade”, that is considered the
new frontier of the treatment of many solid tumors. A phase 3
trial is already testing nivolumab compared to sorafenib as
first-line in HCC patients. BCAAs and nutritional support will
almost certainly play a role in HCC treatment, given their
effect in the maintenance of a good nutritional and functional
status and the possibility of an intrinsic antineoplastic activity.
Maybe in the next future, it will be possible to combine
conventional HCC treatments with other targeted-molecules
and immune check-point inhibitors, in order to obtain a more
effective control of the disease and an improvement of OS;
this could be especially obtained in those patients who have
progressed during sorafenib or who are intolerant to the drug.
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